The Food and Drug Administration (FDA) has granted approval for a higher-dose version of Novo Nordisk’s popular weight loss injection, Wegovy. This move comes as the Danish pharmaceutical company aims to reclaim market share from its chief competitor, Eli Lilly. Novo Nordisk is planning to launch the new 7.2-milligram dose of Wegovy in April, enhancing its product lineup amid fierce competition in the obesity medication market.
The introduction of a higher dosage is strategically designed to better compete with Lilly’s obesity drug Zepbound, which has been recognized for its superior effectiveness in promoting weight loss compared to the standard 2.4-milligram dosage of Wegovy. Zepbound’s greater efficacy has spurred its preference among both prescribers and patients, further cementing Lilly’s dominant position despite entering the U.S. market after Wegovy.
In a phase three clinical trial, the high-dose Wegovy demonstrated significant effectiveness, with participants losing an average of 20.7% of their weight over 72 weeks. In contrast, the standard dose of Wegovy has shown average weight losses of around 15% in prior trials. Dr. Jason Brett, the principal U.S. medical head at Novo Nordisk, noted the additional competitive edge this new dosage provides. He emphasized that it not only narrows the margin in efficacy but also grants patients another option to achieve their weight loss goals, especially for those who do not reach their targets with the standard dosage.
In another phase three trial involving patients suffering from obesity and Type 2 diabetes, the high-dose version of Wegovy resulted in an average weight loss of 14.1%. People with diabetes often face greater challenges in losing weight compared to those without the condition, indicating the potential for the new dosage to make a meaningful impact on this demographic.
This approval also marks a significant milestone as it is the first given to a GLP-1 treatment under the FDA’s new national priority voucher plan. This initiative, launched in June, aims to expedite drug review times to one or two months for companies aligned with U.S. national health priorities.
As the market for obesity medications continues to evolve, Novo Nordisk’s new high-dose Wegovy is poised to be a critical player in addressing the growing demand for effective weight loss solutions.
